|Articles|October 24, 2017

CDC Reports High Vaccination Coverage Among Children Entering Kindergarten

Author(s)Einav Keet

A new CDC report finds that although vaccination coverage is high for kindergarteners in the United States, pockets of undervaccination are a cause for concern among health officials.

A new report from the Centers for Disease Control and Prevention (CDC) shows that while vaccination coverage remains high among children entering kindergarten, exemptions are keeping some states below immunization program targets.

Vaccination requirements for school-aged children are set on a state and local level to prevent the spread of several diseases, including whooping cough, chickenpox, mumps, polio, measles, hepatitis A, among others. In the United States, where outbreaks of vaccine-preventable diseases are now uncommon, the CDC recommends a schedule of immunizations for 14 diseases in children ages 4 to 6 who are beginning school. Students in all states are allowed medical exemptions from vaccination if a child has a health condition that prevents them from receiving a vaccine, and all but two states allow for nonmedical exemptions from vaccination for philosophical or religious reasons. However, a study published earlier this year emphasized the public health consequences of skipping vaccines, with researchers finding that a 5% drop in measles, mumps, rubella (MMR) vaccine coverage would lead to three times more measles cases among children ages 2 to 11 in the United States.

In a new report published in a recent volume of the CDC’s Morbidity and Mortality Weekly Report, researchers looked at vaccination coverage and exemption rates for selected vaccines among kindergarteners during the 2016-2017 school year in the United States, including the District of Columbia. The authors note that the Advisory Committee on Immunization Practices recommends that children who are 4 to 6 years old and starting kindergarten receive 5 doses of diphtheria, tetanus, and acellular pertussis vaccine (DTaP), 2 doses of measles, mumps, and rubella vaccine (MMR), and 2 doses of varicella vaccine, among other immunizations. The report included data collected from 49 states pertaining to required vaccinations among public and private school kindergarteners, as well as exemptions from public schools in 50 states and exemptions from private schools in 49 states. In total, the report included vaccination coverage for about 3,973,172 kindergartners, exemption data for 3,666,870, and provisional or grace period data for 2,463,131.

For the school year, the researchers found that median vaccination coverage was 94.5% for the required number of doses of DTaP, 94.0% for 2 doses of MMR, and 93.8% for 2 doses of varicella vaccine. A median of 2% of kindergartners had an exemption from at least one vaccine, which was similar to the previous school year’s exemption percentage of 1.9%, while 2% of students had a provisional enrollment or grace period that allowed them to attend school while catching up on missing vaccinations. Notable in the report, Alaska, Colorado, Idaho, Indiana, Kansas, and DC reported MMR vaccine coverage of less than 90%, and DTaP vaccine coverage was also less than 90% in Alaska, Arkansas, Colorado, Idaho, Kansas, and DC. California, New York, North Dakota, and Tennessee saw increased coverage for all reported vaccines.

Significant for public health, the report notes that the number of states sharing local-level school vaccination coverage increased from 25 to 30, contributing to transparency and giving communities more information on vaccine-preventable diseases. “Because vaccination coverage and exemption levels are clustered locally, availability of local-level vaccination data can help immunization programs identify schools that might be vulnerable in an outbreak,” write the authors, noting that improved data collection helps health officials understand factors contributing to undervaccination and how to improve vaccine coverage.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.